EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)

Early ecological changes in intestinal microbiota with the long-acting GLP-2 analog apraglutide in short bowel syndrome

Daniel Ekhlas, Astrid Verbiest, Mira Stas, Lise De Meyere, Greet Vandermeulen, Joran Tóth, Karlien Geboers, Lien Timmermans, Chloë Verspecht, Lucas Wauters, Pieter Vermeersch, Palle Bekker Jeppesen und 5 weitere

Clinical Nutrition ESPEN · 2026-06 · 73 · 103138

DOI: 10.1016/j.clnesp.2026.103138 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Nutrition ESPEN, 2026-06. Verfasst von Daniel Ekhlas und 16 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, KULeuven, Leuven, Belgium; Centre for Microbiology, …. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Glucagon-Like Peptide 2, Short Bowel Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Ironwood Pharmaceuticals Inc, Research Foundation Flanders.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIMS: Short bowel syndrome with intestinal failure (SBS-IF) is a rare, severe organ failure condition requiring long-term parenteral support. In SBS with colon-in-continuity (CiC), rapid transit and increased oxygen reshape gut and microbiota. We aimed to elucidate the effects of apraglutide, a novel long-acting glucagon-like peptide-2 (GLP-2) analog, on the gut microbiome in SBS-IF-CiC. METHODS: We performed a 52-week multicenter, open-label, phase 2 study in adults with SBS-IF-CiC (Leuven n = 7, Paris n = 2) receiving weekly subcutaneous apraglutide. Duodenal, distal small bowel and sigmoid colon biopsies, fecal- and plasma samples were collected over time. Analyses included mucosa-associated and fecal microbiota, fecal parameters, and fermentation metabolites. For baseline comparison, duodenal and sigmoid colonic biopsies from 20 controls (10 per region) were collected. RESULTS: Patients exhibited an altered ecosystem characterized by reduced richness, loss of colonic anaerobes and dominance of Lactobacillus and Bifidobacterium with larger inter-subject variability, lower pH, higher moisture, and lower microbial load compared to controls. Apraglutide did not change overall diversity or stool parameters, but reduced inter-subject variability in stool and sigmoid colon. Notably, Bifidobacterium decreased in both stool and sigmoid colon, whereas Prevotella increased in stool from some patients. Still, Lactobacillus remained dominant. Specific taxa correlated with fecal butyrate, propionate, and reduced distal colonic motility, indicating microbial metabolism may support boosted adaptation. CONCLUSIONS: This study emphasizes that SBS-IF-CiC features an immature distal gut microbiota and apraglutide promotes early ecological maturation, suggesting that combining GLP-2 analog therapy with microbiome-targeted strategies may further enhance intestinal and ecosystem adaptation; ClinicalTrials.gov, Number NCT04964986https://www. CLINICALTRIALS: gov/study/NCT04964986?term=NCT04964986&rank=1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeGlucagon-Like Peptide 2Short Bowel SyndromeAdultAgedFemaleHumansMaleMiddle AgedColonFeces

Stichwörter der Autor:innen

ApraglutideColon-in-continuityGLP-2 analogsMicrobiotaShort bowel syndrome

Substanzen

Glucagon-Like Peptide 2

Autor:innen und Institutionen

  • Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, KULeuven, Leuven, Belgium; Centre for Microbiology, Vlaams Instituut voor Biotechnologie (VIB), Leuven, Belgium.
  • Translational Research Centre for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases and Metabolism (ChroMeta), KULeuven, Leuven, Belgium; Leuven Intestinal Failure and Transplantation Centre (LIFT), Un…
  • Translational Research Centre for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases and Metabolism (ChroMeta), KULeuven, Leuven, Belgium.
  • Leuven Intestinal Failure and Transplantation Centre (LIFT), University Hospitals Leuven, Leuven, Belgium.
  • Clinical Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
  • Department of Intestinal Failure and Liver Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Förderung

  • Ironwood Pharmaceuticals Inc
  • Research Foundation Flanders

Zitieren

APA

Ekhlas, D., Verbiest, A., Stas, M., De Meyere, L., Vandermeulen, G., Tóth, J., Geboers, K., Timmermans, L., Verspecht, C., Wauters, L., Vermeersch, P., Jeppesen, P. B., Verbeke, K., Joly, F., Derrien, M., Raes, J., & Vanuytsel, T. (2026). Early ecological changes in intestinal microbiota with the long-acting GLP-2 analog apraglutide in short bowel syndrome. Clinical Nutrition ESPEN, 73, 103138. https://doi.org/10.1016/j.clnesp.2026.103138

Vancouver

Ekhlas D, Verbiest A, Stas M, De Meyere L, Vandermeulen G, Tóth J, et al. Early ecological changes in intestinal microbiota with the long-acting GLP-2 analog apraglutide in short bowel syndrome. Clinical Nutrition ESPEN. 2026;73:103138. doi:10.1016/j.clnesp.2026.103138

BibTeX
@article{Ekhlas2026,
  author = {Ekhlas, Daniel and Verbiest, Astrid and Stas, Mira and De Meyere, Lise and Vandermeulen, Greet and Tóth, Joran and Geboers, Karlien and Timmermans, Lien and Verspecht, Chloë and Wauters, Lucas and Vermeersch, Pieter and Jeppesen, Palle Bekker and Verbeke, Kristin and Joly, Francisca and Derrien, Muriel and Raes, Jeroen and Vanuytsel, Tim},
  title = {Early ecological changes in intestinal microbiota with the long-acting GLP-2 analog apraglutide in short bowel syndrome},
  journal = {Clinical Nutrition ESPEN},
  year = {2026},
  volume = {73},
  pages = {103138},
  doi = {10.1016/j.clnesp.2026.103138}
}
Kostenlos starten →